RNA Atrium Therapeutics, Inc.
$8.32▲ +3.35%
Healthcare
Other
After hours
$8.32▲ +0.00%
Oct 27, 4:00 PM ET
Volume 198.6K
Avg Volume (10D) 210.9K
Key Metrics & Fundamentals
Market Cap
$142.32M
P/E Ratio
–
Div Yield
0.00%
52W Range
7.49 - 16.77
% vs 50 MA
-17.37%
% vs 200 MA
–%
RSI-14
45.5
MACD Histogram
+0.1800
Beta (1Y vs SPY)
1.15
Free Cash Flow
-$3.96M
Gross Rev
$3.00M
Gross Profit
$3.00M
EBITDA
-$22.28M
COGS
–
Operating Exp
$25.62M
Operating Income
-$22.62M
EBIT
-$22.62M
Pretax Income
-$20.19M
Net Income
-$20.19M
EPS (Diluted)
-1.18
Price & Volume History
Loading chart…
Recent News
Atrium Therapeutics Doses First Patient in Phase 1/2 Trial of ATR 1072
MT Newswires · Oct 27, 2026 10:04 AM ET
Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
PR Newswire · Oct 27, 2026 6:30 AM ET
Roth Capital Initiates Atrium Therapeutics at Buy
MT Newswires · Oct 22, 2026 8:16 AM ET
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · Oct 20, 2026 5:23 PM ET
Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing
PR Newswire · Oct 20, 2026 8:09 AM ET
Atrium Therapeutics Announces $50 Million Private Placement
PR Newswire · Oct 8, 2026 6:30 AM ET
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · Sep 21, 2026 4:30 PM ET
Wall Street Money Is Leaving Just As Atrium’s (RNA) Pipeline Turns Real
Insider Monkey · Sep 6, 2026 6:44 AM ET
Atrium Therapeutics to Participate in Upcoming Investor Conferences
PR Newswire · Sep 2, 2026 8:00 AM ET
Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?
Insider Monkey · Aug 28, 2026 3:42 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See RNA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.